ArticleJournal of molecular neuroscience : MN2025
MiR- 142 - 3p Up-regulation Mitigates Cerebral Ischemia-reperfusion Injury by Targeting PICALM.
Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Research has shown that miR-142-3p is vital in numerous ischemic diseases and is strongly linked to apoptosis. The effects and precise mechanisms behind miR-142-3p in cerebral ischemia-reperfusion injury (CIRI) are not yet comprehensively elucidated. The results revealed significant repression in miR-142-3p and elevation in PICALM in the plasma of CIRI individuals. To explore further, middle cerebral artery occlusion (MCAO) rat models and oxygen-glucose deprivation/reoxygenation (OGDR)-induced SH-SY5Y cells were conducted. In brain tissue and SH-SY5Y cells, we employed qRT-PCR and Western blot (WB) to estimate miR-142-3p alongside PICALM expression. Notably, overexpression of miR-142-3p significantly minimized infarct areas and cell apoptosis in ischemic rats, as evidenced by TTC staining and immunohistochemistry. Similarly, miR-142-3p upregulation enhanced cell viability (CV) while suppressing SH-SY5Y cell death under OGDR conditions. The connection between miR-142-3p and PICALM was validated via TargetScan and a luciferase reporter assessment. Rescue experiments were performed to uncover PICALM's involvement in miR-142-3p regulation during ischemic injury. In the presence of OGDR, miR-142-3p overexpression significantly promoted PI3K/Akt pathway activation, but this was mitigated by PICALM overexpression. Overall, miR-142-3p might provide neuroprotective benefits during OGDR injury by affecting PICALM and stimulating PI3K/Akt signaling, rendering it a possible therapeutic CIRI target.
Indexed as
Identifiers
40272654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.